Floatz logo

CLOXACILLIN

Non-Alcoholic Fatty Liver Disease

NorgineSmall moleculePhase 2Dormant
CCC
54/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
42/ 100
Competitive Position
73/ 100

Competitive context

56 Active assets in the Non-Alcoholic Fatty Liver Disease cohort.

Asset / SponsorPhaseRating
Metformin
Xiqiao Zhou
Phase 4BBB
Pioglitazone
Badr University
Phase 4BBB
Semaglutide
Shanghai Jiao Tong University School of Medicine
Phase 4BB
Silymarin
University Hospitals Cleveland Medical Center
Phase 4BB
Letrozole
Jinnah Postgraduate Medical Centre
Phase 4BB

View all 50 →

Same molecule, other indications

CLOXACILLIN is also rated in:

Hepatic CirrhosisDormant
BBB
Indicative ·
73 / 100
View asset →
Nonalcoholic SteatohepatitisDormant
BB
Indicative ·
67 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →